^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CCT301-038

i
Other names: CCT301-038, CCT301-38, CCT3-AXL-0038, CCT301038, CCT301 038, CCT30138, CCT3AXL0038, CCT301 38, CCT3 AXL 0038
Associations
Company:
Exuma Biotech, Sunterra Biotech
Drug class:
AXL-targeted CAR-T immunotherapy
Associations
17d
Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma (clinicaltrials.gov)
P1/2, N=66, Terminated, Shanghai PerHum Therapeutics Co., Ltd. | Active, not recruiting --> Terminated; Adjustment of study strategy
Trial termination • Metastases
|
AXL (AXL Receptor Tyrosine Kinase) • ROR2 (Receptor Tyrosine Kinase Like Orphan Receptor 2)
|
cyclophosphamide • CCT301-038 • CCT301-59
17d
CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas (clinicaltrials.gov)
P1, N=9, Terminated, Shanghai PerHum Therapeutics Co., Ltd. | Trial completion date: Aug 2025 --> Oct 2024 | Recruiting --> Terminated; Adjustment of study strategy
Trial completion date • Trial termination
|
AXL (AXL Receptor Tyrosine Kinase)
|
AXL positive
|
cyclophosphamide • CCT301-038
over1year
CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas (clinicaltrials.gov)
P1, N=9, Recruiting, Shanghai PerHum Therapeutics Co., Ltd. | Trial completion date: Dec 2023 --> Aug 2025 | Trial primary completion date: Feb 2023 --> Aug 2024
Trial completion date • Trial primary completion date
|
AXL (AXL Receptor Tyrosine Kinase)
|
AXL positive
|
cyclophosphamide • CCT301-038
over2years
CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas (clinicaltrials.gov)
P1, N=9, Recruiting, Shanghai PerHum Therapeutics Co., Ltd. | Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Feb 2023
Trial completion date • Trial primary completion date
|
AXL (AXL Receptor Tyrosine Kinase)
|
AXL positive
|
cyclophosphamide • CCT301-038
almost3years
Clinical • New P1 trial
|
AXL (AXL Receptor Tyrosine Kinase)
|
AXL positive
|
CCT301-038
3years
Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma (clinicaltrials.gov)
P1/2, N=66, Active, not recruiting, Shanghai PerHum Therapeutics Co., Ltd. | Trial completion date: Mar 2035 --> Jun 2023 | Trial primary completion date: Jan 2021 --> Jun 2022
Clinical • Trial completion date • Trial primary completion date
|
AXL (AXL Receptor Tyrosine Kinase) • ROR2 (Receptor Tyrosine Kinase Like Orphan Receptor 2)
|
CCT301-038 • CCT301-59